It has been reported that there is an increase in CD38 expression on peripheral immune cells in patients with SLE (76), while the anti-CD38 monoclonal antibody mezagitamab (TAK-079) has shown effectiveness in treating SLE refractory to anti-TNF (179). This evidence concerns the gene TNF and systemic lupus erythematosus.